CN102743764A - Application of RNA interference target sequence of RhoA in preparation of drugs for treatment of glaucoma - Google Patents
Application of RNA interference target sequence of RhoA in preparation of drugs for treatment of glaucoma Download PDFInfo
- Publication number
- CN102743764A CN102743764A CN2012101062966A CN201210106296A CN102743764A CN 102743764 A CN102743764 A CN 102743764A CN 2012101062966 A CN2012101062966 A CN 2012101062966A CN 201210106296 A CN201210106296 A CN 201210106296A CN 102743764 A CN102743764 A CN 102743764A
- Authority
- CN
- China
- Prior art keywords
- rhoa
- sirna
- target sequence
- treatment
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses an application of a RNA interference target sequence of RhoA in preparation of drugs for treatment of glaucoma. With RhoA siRNA prepared according to the RNA interference target sequence 5'-GAAGTCAAGCATTTCTGTC-3' of the RhoA in the present invention, an expression level of RhoA mRNA can be effectively reduced, an expression level of RhoA gene in anterior chamber tissue can be efficiently down-regulated, and stress fiber formation is affected so as to affect changes of cytoskeleton structures and distributions of actin of trabecular meshwork cells, such that trabecular meshwork cell channel configuration is changed, aqueous humor discharge resistance is changed, and intraocular pressure is affected so as to achieve a purpose of treatment of glaucoma.
Description
Technical field:
The invention belongs to the Biochemistry and Molecular Biology field, be specifically related to the application of RNA interfered target sequence in preparation treatment glaucoma medicine of RhoA.
Background technology:
Glaucoma is present second irreversibility blinding property oculopathy in the whole world, and it is one group and raises with intraocular pressure or other multiple factors cause optic nerve lesion, shows as that visual field damage, excavation of optic disc enlarge, the oculopathy of retinal nerve fibre layer atrophy.Glaucoma takes place and the main hazard factor of development is ocular hypertensive existence.
Glaucomatous pathogenesis is not illustrated as yet fully, and it is the main cause that causes primary open angle glaucoma that trabecular reticulum position ah outflow resistance increases the pathologic intraocular pressure rising that causes.The biological function of tm cells and configuration depend on the cytoskeleton of actin fiber and conjugated protein composition thereof.Rho GTP enzyme is the important regulating and controlling factor that the actin cytoskeleton microfilament is set up, and in the adjusting of actin cytoskeleton, plays the role of a nucleus.The Rho subfamily is divided into 6 big types according to its sequence homology in mammal, wherein also extensive the earliest with RhoA research.
At present, antiglaucomatous treatment comprises uses aqueous humor to form inhibitor or the effusive medicine reduction of enhancing sclera tunica uvea intraocular pressure, and improves the operative treatment that filters purpose.And the antiglaucomatous method of medicine has demonstrated multiple whole body and partial toxic and side effects.At present, the Drug therapy of reduction intraocular pressure mainly contains miotic, adrenergic receptor agonist, beta blocker, carbonic anhydrase inhibitors, derivatives of prostaglandins etc.For example, the miotic pilocarpine can play blurred vision and other disadvantageous visual side-effect; Carbonic anhydrase inhibitors can cause nausea, dyspepsia, whole body toxic and side effects such as fatigue and metabolic acidosis; Beta blocker is excited and myovascular inhibited to bronchus, skeleton to heart.This type of side effect can cause reduction of patient's property followed or stopped treatment.Improper in view of the treatment of glaucomatous importance and present conventional medicament more and more comes into one's own to the gene target treatment of glaucoma development foundation property reason; Yet as the gene transfection of one of gene target property treatment means, the safety of its vector virus carrier and moral check become the main cause that limits its clinical practice.For example, present widely used high efficiency transfection carrier slow virus carrier is a kind of viral vector in HIV-1 (HIV-1) source.Because the HIV complicated biological features, its safety is not well solved as yet.
RNA disturbs and is meant that biological double center chain RNA induces a kind of special gene silencing phenomenon of generation.The research of RNAi has in recent years obtained remarkable progress; Make this technology be applied to a plurality of research fields rapidly; Quickened gene function, genetic development, signal are forwarded to the research of mechanism; And this technology has been applied in the gene therapy of cancer and viral disease, also deep day by day at the applied research of ophthalmology.Tolentino adopts laser to break up Br μ ch film and sets up CNV (choroidal neovascularization; CNV) animal model; After adopting vitreous chamber injection of VEGF-siRNA, observe the seepage of angiogenesis situation and new vessels, the result finds that VEGF-siRNA can significantly suppress the generation of CNV; Obviously reduce the seepage of CNV, and do not observe hemorrhage, inflammation, toxic reaction; Nakam μ ra etc. adopt in the intraocular inflammation and Fibrotic rat model of subconjunctival injection phosphate buffered saline (PBS) making, find that TGF-siRNA obviously reduces inflammatory reaction and substrate calmness in the rat model.Yet RNA disturbs and directly reduces the rare research of distribution situation after intraocular pressure is treated glaucomatous application and siRNA injected into anterior chambers at eye.
Summary of the invention:
The purpose of this invention is to provide the application of RNA interfered target sequence in preparation treatment glaucoma medicine of RhoA, the nucleotides sequence of the RNA interfered target sequence of described RhoA is classified as: 5 '-GAAGTCAAGCATTTCTGTC-3 '.
RNA interfered target sequence-RhoA siRNA of the RhoA that the present invention proposes selects the foundation of effective target sequence: 1, with the secondary structure of RNA struct μ re software prediction RhoA mRNA; Select wherein not form the fragment of hair clip, perhaps guaranteeing has tens montages not form hair clip.2,19 bases of fragment have two dT to dangle, and GC content is avoided GGG or CCC 30%～55% as far as possible simultaneously.3, the conservative of checking sequence selects conservative high.
The RNA interfered target sequence of RhoA of the present invention, its nucleotide sequence is following:
5’-GAAGTCAAGCATTTCTGTC-3’。
According to the RNA interference sequence RhoA siRNA of the RNA interfered target sequence of RhoA design, its positive-sense strand is 5 ' GAAGUCAAGCAUUUCUGUC dTdT 3 ', and antisense strand is 3 ' dTdT CUUCAGUUCGUAAAGACAG 5 '.
The present invention is with the RhoA siRNA of RNA interfered target sequence 5 '-GAAGTCAAGCATTTCTGTC-3 ' acquisition of above-mentioned RhoA; With this RhoA siRNA transfection people tm cells (Human trabec μ lar meshwork) and l cell NIH/3T3 and detect its jamming effectiveness; The result finds; As shown in Figure 1; RhoA siRNA can reduce the expression of the mRNA of RhoA gene among vitro human tm cells (Human trabec μ lar meshwork) and the l cell NIH/3T3, and jamming effectiveness can be up to about 80%.Non-specific cy3labeled siRNA is mixed the anterior chamber of reinjecting with transfection reagent; The tobramycin eye ointment is coated with eye, observes cy3labeled siRNA distribution situation in anterior chamber's tissue with immunofluorescence, and the result finds; Shown in Fig. 2 and Fig. 3 A; Overwhelming majority cy3labeled siRNA (red-label among Fig. 2) is present in the trabecular tissue of angle of anterior chamber, and does not find the distribution of cy3labeled siRNA in corneal endothelium and the iris tissue, for further specific gene treatment provides experiment basis.1d, the 7d anterior ocular segment photographic system record eye corneal opacity behind the injected into anterior chambers RhoA siRNA, situation such as iris hyperemia, situation such as crystal transparency; For histological observation, observe the corneal endothelium form with paraffin section HE dyeing, the result finds; As shown in Figure 3, RhoA siRNA does not see tangible toxic reaction at eye, and corneal clouding is not seen in the operation clinical observation; Edema is not seen lenticular opacity.HE dyeing corneal endothelium is no abnormality seen also.At the injected into anterior chambers RhoA of chronic high intraocular pressure mouse model siRNA; The level of detection technique eye varieties of intraocular pressure situation and RhoA mRNA, result are shown in Figure 4 and 5, behind the local eye dripping of dexamethasone; Intraocular pressure raises gradually; To the 28th day about 7mmHg of intraocular pressure rising, injected the back the 5th day at RhoA siRNA, intraocular pressure is reduced to the normal baseline level.RhoAmRNA in the anterior chamber of the chronic high intraocular pressure mouse model that dexamethasone the causes tissue raises, and behind injection RhoA siRNA, it is about 50% that the RhoAmRNA level has descended, and has good transfection efficiency in vivo.This shows; Injection specific fragment RhoA siRNA can efficiently reduce RhoA gene and expression of gene amount in anterior chamber's tissue in the body, influences the formation of stress fiber, and then influences the change of trabecular meshwork cell actin cytoskeleton structure and distribution; Thereby cause the variation of trabecular meshwork cell channel configurations; Change aqueous humor and discharge resistance, and then influence intraocular pressure, thereby reach the glaucomatous purpose of treatment.
Therefore, RNA interfered target sequence 5 '-GAAGTCAAGCATTTCTGTC-3 ' of RhoA of the present invention can be applicable in the preparation treatment glaucoma medicine.
Preferably; RNA interference sequence RhoA siRNA according to the design of the RNA interfered target sequence of described RhoA; Its positive-sense strand is 5 ' GAAGUCAAGCAUUUCUGUC dTdT 3 '; Antisense strand is 3 ' dTdT CUUCAGUUCGUAAAGACAG 5 ', and the glaucomatous medicine of described treatment prepares through following method: with PBS RhoA siRNA is diluted to 2 μ g/ μ l, again 3.5: 1.5 by volume and transfection reagent Lipofectamine
TMThe RNAiMAX hybrid reaction glaucomatous medicine that obtains medical treatment.
Can effectively reduce the expression of RhoA mRNA according to the RhoA siRNA of RNA interfered target sequence 5 '-GAAGTCAAGCATTTCTGTC-3 ' of RhoA of the present invention preparation; The proteic expression of RhoA in the efficient downward modulation anterior chamber tissue influences the formation of stress fiber, and then influences the change of trabecular meshwork cell actin cytoskeleton structure and distribution; Thereby cause the variation of trabecular meshwork cell channel configurations; Change aqueous humor and discharge resistance, and then influence intraocular pressure, thereby reach the glaucomatous purpose of treatment.
Description of drawings:
Fig. 1 is the influence of the transient transfection of siRhoA to people's tm cells and mice 3T3 cell RhoA expression; Wherein Figure 1A representes RhoA gene expression is influenced; Figure 1B representes that wherein last two width of cloth figure represent the influence to the RhoA protein expression of people's tm cells among Figure 1B to the influence of RhoA protein expression, and two width of cloth figure represent the influence to the RhoA protein expression of mice 3T3 cell under among Figure 1B; What contrast was represented is the PBS group; What transfection reagent was represented is to use the transfection reagent group merely, and what negative control was represented is negative control siRNA group, and siRhoA representes RhoA siRNA (siRhoA) and transfection reagent Lipofectamine
TMThe mixed liquor of RNAiMAX (as follows);
Fig. 2 is that cy3labeled siRNA is in anterior chamber's the high density distribution and the distribution situation of before eyes section its hetero-organization thereof.What Fig. 2 A and 2B represented is the distribution situation of 24 hours siRNA anterior chamber of eye behind the injected into anterior chambers 7 μ g cy3labeled siRNA.Wherein that red representative is cy3labeled siRNA, and what blueness was represented is nucleus dyeing.
Fig. 3 is first day and anterior chamber of eye photograph (Fig. 3 B) in the 7th day and a histology HE dyeing situation (Fig. 3 C) after the interior transfection of siRhoA body.Fig. 3 A (a) (b) representes the distribution situation of injected into anterior chambers 7 μ g cy3labeled siRNA at corneal endothelium and iris respectively.That redness is represented is cy3labeled siRNA, and the blue nucleus of representing dyes.Fig. 3 B (c) PBS is injected in representative respectively for a, b, negative control siRNA, and 24 hours anterior chamber of eye are taken a picture behind the siRhoA; (f) PBS is injected in representative to Fig. 3 B respectively for d, e, and negative control siRNA, siRhoA be the anterior chamber of eye photograph after 7 days.(c) PBS is injected in representative to Fig. 3 C respectively for a, b, negative control siRNA, 24HE dyeing behind the siRhoA; (f) PBS is injected in representative to Fig. 3 C respectively for d, e, and negative control siRNA, siRhoA be HE dyeing after 7 days.
Fig. 4 is the situation of varieties of intraocular pressure before and after the siRhoA mice injected into anterior chambers.
Fig. 5 is that transfection efficiency detects in the siRhoA mice body.
The specific embodiment:
Below be to further specify to of the present invention, rather than limitation of the present invention.
Embodiment 1:
1, RhoA siRNA design: according to existing bibliographical information and experiment experience, utilize biosoftware,, design and selected the highest sequence of software scoring according to the RhoA gene order that GenBank delivers.The BLAST software that adopts NCBI GenBank (u.s. national library of medicine and NIH write) to provide at last; Target sequence to selecting carries out the homology analysis, gets rid of the possibility that siRNA suppresses other genetic fragments of mice and people non-specificly.The company of on commission implementation sequence and composition sequence is the sharp rich biological company limited in Guangzhou.
The RNA interfered target sequence of RhoA: 5 '-GAAGTCAAGCATTTCTGTC-3 '
Thus according to the RNA interfered target sequence of RhoA: the nucleotides sequence of the RhoAsiRNA (two strands) of 5 '-GAAGTCAAGCATTTCTGTC-3 ' design is classified as:
Positive-sense strand: 5 ' GAAGUCAAGCAUUUCUGUC dTdT 3 '
Antisense strand: 3 ' dTdT CUUCAGUUCGUAAAGACAG 5 ', called after siRhoA.
2, RhoA siRNA (siRhoA) transfection people tm cells (Human trabecular meshwork) and l cell NIH/3T3 and detect its jamming effectiveness.
Transfection the previous day, people's tm cells that grows fine (Human trabecular meshwork) and l cell NIH/3T3 are used trypsinization, with every hole 1 * 10
5Individual cell inoculation culture fluid of Human trabecular meshwork cell in 12 orifice plates is the DMEM/F12 culture medium of 15% hyclone; The cell culture fluid of NIH/3T3 is the DMEM culture medium of 10% hyclone), treat that cell grows to and can be used as transfection when degrees of fusion is 60%～80% left and right sides.Dilute RhoA siRNA (siRhoA) to 2.8 μ g, again with 5 μ l transfection reagent Lipofectamine with the DMEM culture medium that does not contain hyclone
TMRNA iMAX (Invitrogen) adds in the DMEM culture medium that does not contain hyclone that contains RhoA siRNA (siRhoA) of the above-mentioned dilution of 2ml.With RhoA siRNA (siRhoA) and the transfection reagent Lipofectamine after the dilution
TMRNA iMAX (Invitrogen) is mixing gently, room temperature reaction 30min.With the culture fluid sucking-off in the culture plate, with the DMEM of serum-free washing 2 times and blot.Again with the RhoA siRNA (siRhoA) and the transfection reagent Lipofectamine of above-mentioned preparation
TMThe mixed liquor of RNA iMAX joins in the culture plate, every hole 1ml.Place 37 ℃, 5%CO
2Culture fluid is abandoned in suction after cultivating 4h in the incubator; Wash gently twice with PBS; Add the DMEM culture fluid that contains hyclone and continue to cultivate, with the RhoA changes in gene expression of Real Time PCR detection cell, the RhoA protein expression that detects cell behind the 48h changes behind the 24h.With PBS blank, transfection reagent Lipofectamine
TMRNA iMAX and Negative control (NC) be respectively as matched group, transfection reagent group and negative control group.
The result is as shown in Figure 1; From Fig. 1 (A; B) can find out; RhoA siRNA can reduce expression and the proteic expression of RhoA of the RhoA mRNA among vitro human tm cells (Humantrabec μ lar meshwork) and the l cell NIH/3T3, and jamming effectiveness is about 80%, and its jamming effectiveness is the highest in l cell NIH/3T3.
3, the observation of non-specific cy3labeled siRNA distribution situation in anterior chamber's tissue.
(name of product is: Cy3-NControl_05815 (2-OMe) to dilute non-specific cy3labeled siRNA with PBS; CN is: siB10112100751; Manufacturer:, get 3.5 μ l cy3labeled siRNA and 1.5 μ l transfection reagent Lipofectamine the sharp rich bio tech ltd in Guangzhou) to 2 μ g/ μ l
TMRNA iMAX (Invitrogen) mixes, and room temperature reaction 30min is subsequent use.Get adult mice and accurately weigh, random packet is carried out intraperitoneal anesthesia with 4.3% chloral hydrate by the 0.20-0.33ml/kg standard.Behind the routine disinfection, open eyelid, drip 2 anterior corneal surface anesthesia of tetracaine eye drop.Under operating microscope, extract cut-and-dried cy3 labeled siRNA and transfection reagent Lipofectamine with the 33G microsyringe
TMThe mixture of RNA iMAX gets into the anterior chamber by corneoscleral junction precontract 0.3mm place, does not carefully injure crystal, and slowly mixture is injected the anterior chamber, and the injection back is slowly extracted injection needle out the mixture of each anterior chamber's 5 μ l volume 5 seconds again.The tobramycin eye ointment is coated with eye.Observe cy3 labeled siRNA distribution situation in anterior chamber's tissue with immunofluorescence.
The result is shown in Fig. 2 and Fig. 3 A; Can find out by Fig. 2; Overwhelming majority cy3 labeled siRNA (red fluorescence among Fig. 2) is present in the trabecular tissue of angle of anterior chamber; And do not find the distribution (Fig. 3 A) of a large amount of cy3 labeledsiRNA in corneal endothelium and the iris tissue, for further specific gene treatment provides experiment basis.
4, the toxic research of RhoA siRNA ophthalmic
With PBS dilution RhoA siRNA to 2 μ g/ μ l, get 3.5 μ l again with transfection reagent Lipofectamine
TMRNA iMAX (Invitrogen) 1.5 μ l mix, and room temperature reaction 30min is subsequent use.Under operating microscope, extract cut-and-dried RhoA siRNA and transfection reagent Lipofectamine with the 33G microsyringe
TMThe mixture of RNA iMAX gets into the anterior chamber by the corneoscleral junction precontract 0.3mm place of adult mice, does not carefully injure crystal, and slowly mixture is injected the anterior chamber; Slowly extract injection needle out for 5 seconds the injection back again; The mixture of each anterior chamber's 5 μ l volume, 1d, the anterior ocular segment photographic system record eye corneal opacity behind the 7d; Situation such as iris hyperemia, situation such as crystal transparency.For histological observation, observe the corneal endothelium form with paraffin section HE dyeing.Its result such as Fig. 3 (B, C) shown in, as can beappreciated from fig. 3, RhoA siRNA (siRhoA) does not see tangible toxic reaction at eye, the operation clinical observation do not see corneal clouding, edema is not seen lenticular opacity.HE dyeing corneal endothelium is no abnormality seen also.
5, varieties of intraocular pressure curve before and after chronic high intraocular pressure mouse model of preparation and the detection injected into anterior chambers RhoA siRNA (siRhoA).
Get 6 all adult mices and accurately weigh, be divided into 5 groups at random.Wherein one group with PBS eye water spot left eye, and other four groups with 1% dexamethasone eye water spot eye, four times a day, totally 28 days in addition.Detect an intraocular pressure in per 7 days with TONO-PEN AVIA applanation tonometer during this time, and write down and describe the intraocular pressure curve chart.With PBS dilution RhoA siRNA to 2 μ g/ μ l, get 3.5 μ l again with transfection reagent Lipofectamine
TMRNA iMAX (Invitrogen) 1.5 μ l mix, and room temperature reaction 30min is subsequent use.Under operating microscope, extract cut-and-dried RhoA siRNA and transfection reagent Lipofectamine with the 33G microsyringe
TMThe mixture of RNAiMAX gets into the anterior chamber by corneoscleral junction precontract 0.3mm place, does not carefully injure crystal, and slowly mixture is injected the anterior chamber, and slowly extract injection needle out for 5 seconds the injection back again; The mixture of each anterior chamber's 5 μ l volume is in postoperative 1d, 2d, 3d; 4d, 5d, 6d; 7d, 14d, 21d detection technique eye varieties of intraocular pressure situation.The result was as shown in Figure 4, and as can be seen from Figure 4, behind the local eye dripping of dexamethasone, intraocular pressure raises gradually, to the 28th day about 7mmHg of intraocular pressure rising.Injected the back the 5th day at RhoA siRNA, intraocular pressure is reduced to the normal baseline level.Use transfection reagent Lipofectamine
TMRNAiMAX, dexamethasone and PBS do same treatment, and negative control is Negative control siRNA.
6, transfection and detect its jamming effectiveness in RhoA siRNA (siRhoA) body
Get 6 all adult mices and accurately weigh, with 1% dexamethasone eye water spot eye, four times a day totally 28 days, obtains chronic high intraocular pressure mouse model thus.With PBS dilution RhoA siRNA to 2 μ g/ μ l, get 3.5 μ l again with transfection reagent Lipofectamine
TMRNAiMAX (Invitrogen) 1.5 μ l mix, and room temperature reaction 30min is subsequent use.The time of injection RhoA siRNA is dexamethasone eye dripping after 28 days, and the 29th day begins to make an experiment.Get chronic high intraocular pressure mouse model, random packet is carried out intraperitoneal anesthesia with 4.3% chloral hydrate by the 0.20-0.33ml/kg standard.Behind the routine disinfection, open eyelid, drip 2 anterior corneal surface anesthesia of tetracaine eye drop.Under operating microscope, extract cut-and-dried RhoAsiRNA and transfection reagent Lipofectamine with the 33G microsyringe
TMThe mixture of RNA iMAX gets into the anterior chamber by corneoscleral junction precontract 0.3mm place, does not carefully injure crystal, and slowly mixture is injected the anterior chamber, and the injection back is slowly extracted injection needle out the mixture of each anterior chamber's 5 μ l volume 5 seconds again.Detect the transfection efficiency of intravital RhoA gene with RT-PCR.Use transfection reagent Lipofectamine
TMRNA iMAX and dexamethasone are done same treatment, with PBS and Negative control respectively as blank and negative control.
The result is as shown in Figure 5; Can find out that by Fig. 5 the RhoAmRNA in anterior chamber's tissue of the chronic high intraocular pressure mouse model that dexamethasone causes raises, behind injection RhoA siRNA (siRhoA); It is about 50% that the RhoAmRNA level has descended, and has good transfection efficiency in vivo.This shows; Injection RhoA siRNA can efficiently reduce RhoA expression of gene amount in anterior chamber's tissue in the body, influences the formation of stress fiber, and then influences the change of trabecular meshwork cell actin cytoskeleton structure and distribution; Thereby cause the variation of trabecular meshwork cell channel configurations; Change aqueous humor and discharge resistance, and then influence intraocular pressure, thereby reach the glaucomatous purpose of treatment.
In sum, the present invention can be used for preparation treatment glaucoma medicine according to the RhoA siRNA of RNA interfered target sequence 5 '-GAAGTCAAGCATTTCTGTC-3 ' preparation of RhoA.
Claims (2)
1.RhoA the application of RNA interfered target sequence in preparation treatment glaucoma medicine, the nucleotides sequence of the RNA interfered target sequence of described RhoA is classified as: 5 '-GAAGTCAAGCATTTCTGTC-3 '.
2. application according to claim 1; It is characterized in that; According to the RNA interference sequence RhoA siRNA of the RNA interfered target sequence of described RhoA design, its positive-sense strand is 5 ' GAAGUCAAGCAUUUCUGUC dTdT 3 ', and antisense strand is 3 ' dTdT CUUCAGUUCGUAAAGACAG 5 '; The glaucomatous medicine of described treatment prepares through following method: with PBS RhoA siRNA is diluted to 2 μ g/ μ l, again 3.5: 1.5 by volume and transfection reagent Lipofectamine
TMThe RNAiMAX hybrid reaction glaucomatous medicine that obtains medical treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101062966A CN102743764A (en) | 2012-04-11 | 2012-04-11 | Application of RNA interference target sequence of RhoA in preparation of drugs for treatment of glaucoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101062966A CN102743764A (en) | 2012-04-11 | 2012-04-11 | Application of RNA interference target sequence of RhoA in preparation of drugs for treatment of glaucoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102743764A true CN102743764A (en) | 2012-10-24 |
Family
ID=47024486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101062966A Pending CN102743764A (en) | 2012-04-11 | 2012-04-11 | Application of RNA interference target sequence of RhoA in preparation of drugs for treatment of glaucoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102743764A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113842473A (en) * | 2021-10-13 | 2021-12-28 | 青岛大学 | Bimodal nanoprobe for trabecular cell labeling and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102272307A (en) * | 2008-11-21 | 2011-12-07 | 利莱恩斯生命科学有限公司 | Inhibition of vegf-a secretion, angiogenesis and/or neoangiogenesis by sina mediated knockdown of vegf-c and rhoa |
-
2012
- 2012-04-11 CN CN2012101062966A patent/CN102743764A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102272307A (en) * | 2008-11-21 | 2011-12-07 | 利莱恩斯生命科学有限公司 | Inhibition of vegf-a secretion, angiogenesis and/or neoangiogenesis by sina mediated knockdown of vegf-c and rhoa |
Non-Patent Citations (5)
| Title |
|---|
| 《Cell Signal》 20090630 Raja Bhattacharyya et al Differences in Galpha12-and Galpha13-mediated plasma membrane recruitment of p115-RhoGEF 996-1006 1-2 第21卷, 第6期 * |
| CHRISTINE VARON ET AL: "Transforming growth factor B induces rosettes of podosomes in primary aortic endothelial cells", 《MOLECULAR AND CELLULAR BIOLOGY》, vol. 26, no. 9, 31 May 2006 (2006-05-31), pages 3582 - 3594 * |
| FANNY MOMBOISSE ET AL: "BETA PIX-activated Rac 1 stimulates the activation of phospholipase D, which is associated with exocytosis in neuroendocrine cells", 《J CELL SCI》, vol. 122, no. 6, 15 March 2009 (2009-03-15), pages 798 - 806 * |
| PHILIPP PETERMANN ET AL: "Impact of Rac1 and Cdc42 signaling during early herper simplex virus type 1 infection of keratinocytes", 《JOURNAL OF VIROLOGY》, vol. 83, no. 19, 29 July 2009 (2009-07-29), pages 9759 - 9772 * |
| RAJA BHATTACHARYYA ET AL: "Differences in Gα12-and Gα13-mediated plasma membrane recruitment of p115-RhoGEF", 《CELL SIGNAL》, vol. 21, no. 6, 30 June 2009 (2009-06-30), pages 996 - 1006 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113842473A (en) * | 2021-10-13 | 2021-12-28 | 青岛大学 | Bimodal nanoprobe for trabecular cell labeling and preparation method and application thereof |
| CN113842473B (en) * | 2021-10-13 | 2024-01-30 | 青岛大学 | Bimodal nanoprobe for trabecular cell labeling, and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kurz et al. | Biaxial microincision versus coaxial small-incision clear cornea cataract surgery | |
| Das et al. | Vimentin knockdown decreases corneal opacity | |
| Gupta et al. | RNA therapeutics in ophthalmology-translation to clinical trials | |
| Zhang et al. | LncRNA NEAT1 sponges MiRNA-148a-3p to suppress choroidal neovascularization and M2 macrophage polarization | |
| Yang et al. | MiR-126 overexpression inhibits high glucose-induced migration and tube formation of rhesus macaque choroid-retinal endothelial cells by obstructing VEGFA and PIK3R2 | |
| CN102048756A (en) | Use of human fat-derived mesenchymal stem cells in treatment of diseases in kidney and ocular fundus | |
| CN103068981A (en) | Sirna targeting VEGFA and methods for treatment in VIVO | |
| WO2024045251A1 (en) | Small interfering rna for treating neovascular retinal diseases and dna tetrahedral complex thereof | |
| Gerhart et al. | Depletion of Myo/Nog cells in the lens mitigates posterior capsule opacification in rabbits | |
| CN102743763B (en) | Drug for treating glaucoma | |
| Shen et al. | Preclinical evaluation of a phosphorothioate oligonucleotide in the retina of rhesus monkey | |
| CN110106248B (en) | Application of circular RNA hsa _ circ _0001543 in preparation of retinal degeneration disease diagnostic reagent | |
| CN102743764A (en) | Application of RNA interference target sequence of RhoA in preparation of drugs for treatment of glaucoma | |
| Fan et al. | MicroRNA-126 inhibits pathological retinal neovascularization via suppressing vascular endothelial growth factor expression in a rat model of retinopathy of prematurity | |
| Tian et al. | A potential application of canaloplasty in glaucoma gene therapy | |
| TWI585205B (en) | Microrna-328 anti-sense composition and therapeutic use | |
| Yuan et al. | Lentivirus-mediated RNA interference of vascular endothelial growth factor in monkey eyes with iris neovascularization | |
| JP2022000035A (en) | Sirna and their use in methods and compositions for inhibiting expression of nrarp gene | |
| CN101857860B (en) | Application of viral nucleic acid sequence strictly conservative area as siRNA design template | |
| CN104781402A (en) | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions | |
| CN108721315A (en) | Applications of the small molecule nucleic acid miR-21 in treating glaucoma | |
| Li et al. | Silencing of rac1 expression via rna interference inhibits retinal neovascularization in rats | |
| WO2024045250A1 (en) | Dna tetrahedral pharmaceutical complex for treating neovascular retinal diseases, preparation method therefor, and use thereof | |
| Zhang et al. | miR-196b-5p regulates inflammatory process and migration via targeting Nras in trabecular meshwork cells | |
| CN102727513B (en) | Small RNAs targeting tissue factor (TF) gene and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121024 |